ADIL: Adial Pharmaceuticals, Inc. Stock

by  •  • Comments Off on ADIL: Adial Pharmaceuticals, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 4.73
Enterprise Value ($M) 0.98
Book Value ($M) 4.07
Book Value / Share 0.62
Price / Book 1.16
NCAV ($M) 3.08
NCAV / Share 0.47
Price / NCAV 1.53

Profitability (mra)
Return on Invested Capital (ROIC) -3.24
Return on Assets (ROA) -2.79
Return on Equity (ROE) -3.23

Liquidity (mrq)
Quick Ratio 4.16
Current Ratio 4.16

Balance Sheet (mrq) ($M)
Current Assets 4.06
Assets 5.04
Liabilities 0.98
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -8.28
Net Income -13.20
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -6.92
Cash from Investing 0.00
Cash from Financing 7.85

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
11-14 13G/A Armistice Capital, Llc 4.99 101.42

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-03-04 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION
2024-11-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT
2024-08-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO S
2024-05-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO
2024-04-01 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-03-21 14,268 55,204 25.85
2025-03-20 28,681 106,406 26.95
2025-03-19 5,416 31,503 17.19
2025-03-18 15,390 51,788 29.72
2025-03-17 29,384 62,459 47.05

(click for more detail)

Similar Companies
ACB – Aurora Cannabis Inc. ACHV – Achieve Life Sciences, Inc.
ACXP – Acurx Pharmaceuticals, Inc. ADTX – Aditxt, Inc.
ADVM – Adverum Biotechnologies, Inc.


Financial data and stock pages provided by
Fintel.io